BridgeMD
Compares treatment options for Acute Coronary Syndrome
Official title Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
ClinicalTrials.gov ID: NCT04240834
What this study is testing
What is Aspirin?
Aspirin is an investigational medicine, given as an once-daily, being studied as a potential treatment for acute coronary syndrome.
Also referred to as Acetylsalicylic Acid.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events after percutaneous coronary intervention (PCI) and stent implantation.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- ACS patients at high risk for ischemic events after successful PCI with implantation of at least one drug eluting stent
- Able and willing to provide informed consent and participate in 12 months follow-up period
- Able to receive DAPT treatment
- Enrollment into the study will require meeting at least one angiographic or clinical inclusion and none of the
You likely can't join if
- . Clinical inclusion criteria:
- Family history of premature coronary heart disease (Coronary heart disease in first-degree male relative \<55 years old or in first-degree female...
- Repeated myocardial infarction
- Positive serum cardiac troponin I/T
- Combined with at least one organ/system with atherosclerotic disease (e.g. intracranial or peripheral arteries)
- Type 2 diabetes mellitus under medication
See the full eligibility criteria
- ACS patients at high risk for ischemic events after successful PCI with implantation of at least one drug eluting stent
- Able and willing to provide informed consent and participate in 12 months follow-up period
- Able to receive DAPT treatment
- Enrollment into the study will require meeting at least one angiographic or clinical inclusion and none of the
- . Clinical inclusion criteria:
- Family history of premature coronary heart disease (Coronary heart disease in first-degree male relative \<55 years old or in first-degree female relative \<65 years old)
- Repeated myocardial infarction
- Positive serum cardiac troponin I/T
- Combined with at least one organ/system with atherosclerotic disease (e.g. intracranial or peripheral arteries)
- Type 2 diabetes mellitus under medication
- Chronic kidney disease (eGFR\<60 mL/min/1.73 m2 or CrCl\<60ml/min) Angiographic Inclusion Criteria:
- LM lesion requiring stents
- Proximal LAD lesion(s) requiring stents
- Bypass grafts lesion(s) requiring stents
- Overall stent length ≥60 mm
- History of in-stent thrombosis
- Bifurcation lesions requiring at least 2 stents
- Over two vessels lesions requiring stents
- Calcified target lesion(s) requiring atherectomy
- The intraoperative occurrence of no-reflow or slow-flow
- Compressed branch vessels with a diameter of at least 2.0 mm failing to reach flow restoration (at least TIMI 3) Exclusion Criteria:
- Need for chronic oral anticoagulation
- With cardiomyopathy（HCM/DCM/RCM）
- With severe ventricular arrhythmia requiring ICD implantation
- With chronic respiratory disease (COPD, asthma, chronic bronchitis, pulmonary heart disease)
- With severe infectious disease（active hepatitis B, active hepatitis C, AIDS）
- With hematological disorders（thrombocytopenia, severe anemia, leukaemia）
- With severe liver disease or kidney failure
- With malignant tumor
- With cognitive impairment
- Unable or unwilling to provide informed consent or undergo follow-up
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.